Background
==========

HIV-1 diversity presents a challenge for the development of an effective HIV vaccine. Cameroon in central Africa, exhibits very broad HIV-1 genetic diversity. That makes it one of the few places in the world where vaccine efficacy can be tested against a broad range of subtypes and recombinants. The aim of the study is to assess cross-clade T cell responses in HIV-infected Cameroonians.

Methods
=======

PBMCs were obtained from 36 HIV-1 infected blood donors. T cell responses were determined using the IFNγ ELISPOT assay using cryopreserved PBMC. Cells were stimulated with overlapping peptide pools derived from HIV-1 group M consensus Gag and Nef proteins. The first line assay used a pool-matrix screening approach, and this was followed by a confirmatory assay to identify single reactive peptides.

Results
=======

Thirty-six samples were tested in the IFNγ ELISPOT assay; 32 (89%) responded to at least 1 peptide pool. The median magnitude response was 1995 spot forming units (SFU)/106 PBMC among the responders (range 130 to 12853). At the protein level the median response to Gag was 1083 SFU/106 PBMC, while the median response to Nef was 1070 SFU/106 PBMC. The median number of peptides recognized per individual was 5 (range 1 to 16) with no difference in number of peptides recognized in Gag and Nef (p = 0.1793). Most of the reactive peptides targeted the conserved regions both in Gag and Nef. The magnitude of the total response correlated inversely with CD4 count (r = -0.4026 p = 0.0165), but no relationship with viral load was evident. At the protein level, there was no relationship between the Gag or Nef response and CD4 count or viral load.

Conclusion
==========

These data show that high magnitude T cell responses are detectable in HIV-1 infected Cameroonians using Group M peptide reagents, which likely reflects the broad HIV-1 genetic diversity in the population.
